by S. C.

Selenium This mineral influences your immune system mainly by its antioxidant function. it protects your body from the excess oxidative stress created by bacteria, viruses, or pathogens. Deficiency of selenium reduces the antibody response and causes impaired immunity. in a double-blind study conducted in the UK, 22 adults with low selenium levels were given 50 or 100 micrograms (mcg) of selenium or placebo daily for 15 weeks. This was followed by a polio vaccine six weeks later with an intravenous dose of selenium. Selenium supplements helped enhance the immune respond in participants? cells and helped the body more quickly produce T cells and T helper cells (important immune cells that fight invaders). another randomized, placebo-controlled study gave a high selenium yeast supplement (200 mcg a day) or placebo to in 450 HIV-positive adults. Results showed that the mineral suppressed the progression of HIV virus. in this amazing way, selenium may be a simple and inexpensive complementary treatment for AIDS. Zinc This essential mineral helps produce cells, including those used in the immune system. the immune system depends on an adequate amount of zinc in the body. in zinc deficiency, the overall immune system is impaired. This leads to a higher incidence of infectious diseases. Zinc supplements have been shown to reduce the incidence of diarrhea by 18% and pneumonia by 41%. there are many other diseases for which zinc have shown a protective effect, including chronic hepatitis C, leprosy, tuberculosis, and acute lower respiratory infection. the effects on the common cold and malaria are inconclusive. Zinc supplements were ineffective in boosting most vaccines and in alleviating symptoms related to rheumatoid arthritis.

by S. C. 23 July 2011 Teatro Naturale International n. 7 Year 3 © REPRODUCTION RESERVED

Multiple (multiple) inflammatory Entmarkungsherde, probably caused by the attack of endogenous immune cells on the Myelinscheiden the Nervenzellforts?tze are scattered in the white matter of the brain and spinal cord in multiple sclerosis. because the Entmarkungsherde in the entire central nervous system can occur, the multiple sclerosis can cause almost any neurological symptom . Visually impaired with reduction of Visual acuity and errors of the eye movement (internukle?re ophthalmoplegia) are typical, but not specific for multiple sclerosis.

The disease is not curable, but of course can often conveniently be influenced by various measures. Contrary to popular belief, the multiple sclerosis not inevitably leads to severe disabilities. Many years after the onset of the disease, the majority of patients is still capable of walking.

The first symptoms occur mostly between the age of 15 and 40. within the framework of a push. while the episodes at the beginning of the disease completely recede, neurological deficits remain present in the later course of the disease to batch mode. Vision and sensitivity disorders are frequently seen at the beginning of the disease. Often, the disease starts first with an isolated impact, for which the term of clinically isolated syndrome (CIS) has naturalized.

Which symptom in the single thrust occurs is dependent on the respective localization of active Entmarkungsherdes in the central nervous system: to cause inflammation in the area of optic nerve (optic neuritis) Visual impairment, which can become noticeable as Visual blur or Milky veil and also accompanied by sore eyes. Inflammation in the area of sensitive railway systems can cause sensitivity disturbances such as abnormal sensations (paresthesia), numbness, and pain. Often the hands and legs (feet and lower legs) are affected. Pain can be caused by a trigeminal neuralgia, muscle cramps, as well as by the Lhermitte Symptom .[68] The Lhermitte sign is considered typical for the MS and may be a reference to herd in the area of the neck part of the spinal cord. The motor system is affected, paralysis (palsy) of the extremities encounter, where by abnormal involuntary increasing of muscle tone (spastic tone increase) the mobility of patients can be additionally constrained. Herd in brain stem and cerebellum can result in errors of the eye movements (diplopia and Nystagmen), swallowing disorders (dysphagia), dizziness and errors of movement coordination (ataxia) and speech impediments (dysarthria). Charcot’s triad refers the Entmarkungsherden common in the area of the upper cerebellar stem syndrome of intention, nystagmus, and skandierender (abgehackter) language. A temporal Abblassung of optic papillae, the existence of a Paraspastik and the absence of the abdominal hautreflexe is referred to as Marburg’s triad . Vegetative centres and trains are affected, it can come to errors of the control of the bladder and bowel function and sexual dysfunction. in many patients, an increased physical and mental fatigue (fatigue) occurs in the course. this fatigue occurs regardless of physical and mental stress and increases in the course of the day. as also the other symptoms can increase the fatigue in the framework of the Uhthoff phenomenon (clearer emergence of symptoms by temperature rise). Cognitive and mental disorders are not to neglect. in particular errors of affect occurs often.[69] in the late stage can occur even a subcortical dementia.

A means to quantify the impact of the patient is to determine which expanded disability status scale (EDSS). The current deterioration of the person concerned in seven neurological systems is determined in this scale. If you look at the entire history of the disease, there are the fatigue, errors of bladder function, as well as errors of the motor system such as paralysis and spastic tone increases, affecting the lives of those affected most often.

So far it is hardly possible to make a forecast on the course, at the beginning of the disease which charged to the patient. some epidemiological studies on the prognosis of multiple sclerosis have been published in recent years. The results were overwhelmingly positive, and showed that the disease is not often less difficult than generally assumed.[125] A Web based computer program for the determination of individual risk profile based on disease progression, is based on the disease development of 1059 patients, by a Munich team expanded disability status scale, disease duration, shear rate and age has been developed

Sergio Pal is owner of Allaboutms.com a website offers all types of information about What is Multiple Sclerosis, symptoms and related articles.

Public release date: 7-Mar-2011 [ | E-mail | Share ] Contact: Michael C. Purdypurdym@wustl.edu314-286-0122Washington University School of Medicine

Scientists have blocked harmful immune cells from entering the brain in mice with a condition similar to multiple sclerosis (MS).

According to researchers from Washington University School of Medicine in St. Louis, this is important because MS is believed to be caused by misdirected immune cells that enter the brain and damage myelin, an insulating material on the branches of neurons that conduct nerve impulses.

New insights into how the brain regulates immune cell entry made the accomplishment possible. Washington University scientists had borrowed an anti-cancer drug in development by the company ChemoCentryx simply to test their theories.

“The results were so dramatic that we ended up producing early evidence that this compound might be helpful as a drug for MS,” says Robyn Klein, MD, PhD, associate professor of pathology and immunology, of medicine and of neurobiology. “The harmful immune cells were unable to gain access to the brain tissue, and the mice that received the highest dosage were protected from disease.”

ChemoCentryx is now testing the drug in Phase I safety trials. the study is published in the Journal of Experimental Medicine.

Klein and her colleagues discovered a chemical stairway that immune cells have to climb down to enter the brain. Immune cells that exit the blood remain along the vessels on the tissue side, climbing down from the meninges into the brain where they can then cross additional barriers and attack myelin on the branches of neurons.

“The effect of immune cell entry into the brain depends on context,” Klein says. “In the case of viral infection, immune cell entry is required to clear the virus. But in autoimmune diseases like multiple sclerosis, their entry is associated with damage so we need to find ways to keep them out.”

The stairway is located on the tissue side of the microvasculature, tiny vessels that carry blood into the central nervous system. the steps are made of a molecule called CXCL12 that localizes immune cells, acting like stairs that slow them down so that they can be evaluated to determine if they are allowed to enter the brain. Klein’s lab previously discovered that the blood vessel cells of the microvasculature display copies of this molecule on their surfaces.

Klein also found that MS causes CXCL12 to be pulled inside blood vessel cells in humans and mice, removing the stairway’s steps and the checkpoints they provide. In the new paper, she showed that blocking the internalization of the molecule prevented immune cells from getting into the brain and doing harm.

Work by another lab called Klein’s attention to CXCR7, a receptor that binds to CXCL12. she showed that the receptor is made by the same cells in the microvasculature that display CXCL12. they watched the receptor take copies of CXCL12 and dump them in the cells’ lysosomes, pockets for breakdown and recycling of molecules the cell no longer needs.

“After it dumps its cargo in the lysosome, the receptor can go right back to the cell surface to pull in another copy of CXCL12,” Klein says. “There likely exists an equilibrium between expression and disposal of CXCL12. Some of the proteins expressed by the immune cells in MS patients affect CXCR7 expression and activity, disrupting the equilibrium and stripping the steps from this immune cell stairway we’re studying.”

Klein contacted researchers at ChemoCentryx, who were developing a blocker of the CXCR7 receptor as a cancer treatment. When they gave it to the mouse model of MS, immune cells stopped at the meninges.

Klein also found that immune factors could cause microvasculature cells to make more or less of CXCR7, ramping up or down the number of steps on the chemical stairway. she is currently investigating additional immune factors that impact on CXCR7 activity within the blood vessel cell. Whether a given factor promotes or suppresses the receptor may also differ depending upon what part of the brain is being considered.

“One of the biggest questions in MS has been why the location, severity and progression of disease varies so much from patient to patient,” Klein says. “Getting a better understanding of how these factors regulate immune cell entry will be an important part of answering that question.”

###

Cruz-Orengo L, Holman DW, Dorsey D, Zhou L, Zhang P, Wright M, McCandless EE, Patel JR, Luker GD, Littman DR, Russell JH, Klein RS. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. the Journal of Experimental Medicine, Feb. 7, 2011.

Funding from the National Institutes of Health, the National Institute of Neurological Disorders and Stroke and the National Multiple Sclerosis Society supported this research.

Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. the School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked fourth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

[ | E-mail | Share ]  

Washington, Mar 8 : Researchers at the Washington University School of Medicine have managed to block the development of multiple sclerosis-like symptoms using a mouse model of the disease.

When scientists gave mice a drug that suppressed the activity of a key molecule, immune cells lined up at the boundaries of the spine instead of going in. Scientists have blocked harmful immune cells from entering the brain in mice with a condition similar to multiple sclerosis (MS).

It is important because MS is apparently caused by misdirected immune cells that enter the brain and damage myelin-an insulating material on the branches of neurons that conduct nerve impulses, said researchers.

“the results were so dramatic that we ended up producing early evidence that this compound might be helpful as a drug for MS. the harmful immune cells were unable to gain access to the brain tissue, and the mice that received the highest dosage were protected from disease,” said Robyn Klein.

Klein and her colleagues discovered a chemical stairway that immune cells have to climb down to enter the brain. Immune cells that exit the blood remain along the vessels on the tissue side, climbing down from the meninges into the brain where they can then cross additional barriers and attack myelin on the branches of neurons.

“the effect of immune cell entry into the brain depends on context. in the case of viral infection, immune cell entry is required to clear the virus. but in autoimmune diseases like multiple sclerosis, their entry is associated with damage so we need to find ways to keep them out,” said Klein.

The stairway is located on the tissue side of the microvasculature, tiny vessels that carry blood into the central nervous system. the steps are made of a molecule called CXCL12 that localizes immune cells, acting like stairs that slow them down so that they can be evaluated to determine if they are allowed to enter the brain.

Klein’s lab previously discovered that the blood vessel cells of the microvasculature display copies of this molecule on their surfaces.

Klein also found that MS causes CXCL12 to be pulled inside blood vessel cells in humans and mice, removing the stairway’s steps and the checkpoints they provide.

In the new paper, she showed that blocking the internalization of the molecule prevented immune cells from getting into the brain and doing harm.

Work by another lab called Klein’s attention to CXCR7, a receptor that binds to CXCL12. she showed that the receptor is made by the same cells in the microvasculature that display CXCL12. they watched the receptor take copies of CXCL12 and dump them in the cells’ lysosomes, pockets for breakdown and recycling of molecules the cell no longer needs.

Klein contacted researchers at ChemoCentryx, who were developing a blocker of the CXCR7 receptor as a cancer treatment. When they gave it to the mouse model of MS, immune cells stopped at the meninges.

The findings have been published in the Journal of Experimental Medicine. (ANI)